UT Southwestern Medical Center, Dallas, Texas, USA.
Children's Medical Center, Dallas, Texas, USA.
Gastrointest Endosc. 2015;81(6):1408-16. doi: 10.1016/j.gie.2014.11.022. Epub 2015 Feb 14.
Risk factors for the development of post-ERCP pancreatitis (PEP) have not been identified in the pediatric population. It remains unclear what constitutes appropriate prophylaxis in this patient population.
To assess the prevalence and severity of PEP in the pediatric population and identify factors associated with developing PEP and to evaluate the effect of prophylactic pancreatic duct stenting in high-risk patients.
Retrospective analysis of an ERCP database at a single large pediatric center.
Academic center.
A total of 432 ERCPs performed on 313 patients younger than 19 years of age from January 2004 to October 2013.
ERCP for any indication.
Rates and severity of PEP, preprocedural and procedural risk factors for the development of PEP, and the effect of pancreatic stents on preventing PEP in high-risk patients.
PEP occurred after 47 procedures (prevalence, 10.9%). Thirty-four cases were mild, 9 were moderate, and 4 were severe. There was no mortality. On multiple logistic analysis, pancreatic duct injection (P<.0001; odds ratio 30.8; 95% confidence interval [CI], 9.1-103.9) and pancreatic sphincterotomy (P<.01; OR 3.8; 95% CI, 1.6-9.8) were positively associated with PEP. A history of chronic pancreatitis was negatively associated with PEP (P<.05; OR 0.37; 95% CI, 0.15-0.93). On subset analysis, placing a prophylactic pancreatic stent was associated with significantly increased rates of PEP in patients with pancreatic duct injection compared with those who had no attempt at stent placement (P<.01). Two patients with severe pancreatitis had prophylactic pancreatic stents in place.
Retrospective investigation.
In the pediatric population, pancreatic duct injection and pancreatic sphincterotomy are associated with significantly increased rates of PEP, whereas a history of chronic pancreatitis is negatively associated. Prophylactic pancreatic stenting is associated with higher rates of PEP in high-risk patients and does not eliminate severe PEP.
在儿科人群中,尚未确定发生内镜逆行胰胆管造影术(ERCP)后胰腺炎(PEP)的危险因素。在儿科人群中,尚不清楚何种情况下适合预防性胰管支架置入。
评估儿科人群中 PEP 的发生率和严重程度,确定与 PEP 发生相关的因素,并评估高危患者预防性胰管支架置入的效果。
在一家大型儿科中心的 ERCP 数据库中进行回顾性分析。
学术中心。
2004 年 1 月至 2013 年 10 月期间,共有 313 名年龄小于 19 岁的患者接受了 432 例 ERCP。
ERCP 用于任何适应证。
PEP 的发生率和严重程度,PEP 发生的术前和术中危险因素,以及胰管支架置入对高危患者预防 PEP 的效果。
47 例(发生率 10.9%)术后发生 PEP。34 例为轻度,9 例为中度,4 例为重度。无死亡病例。多因素逻辑分析显示,胰管注射(P<0.0001;优势比 30.8;95%置信区间 [CI],9.1-103.9)和胰管括约肌切开术(P<0.01;OR 3.8;95% CI,1.6-9.8)与 PEP 呈正相关。慢性胰腺炎病史与 PEP 呈负相关(P<0.05;OR 0.37;95% CI,0.15-0.93)。在亚组分析中,与未尝试放置支架的患者相比,在胰管注射患者中放置预防性胰管支架与 PEP 发生率显著增加相关(P<0.01)。2 例重度胰腺炎患者放置了预防性胰管支架。
回顾性研究。
在儿科人群中,胰管注射和胰管括约肌切开术与 PEP 发生率显著增加相关,而慢性胰腺炎病史则与之呈负相关。预防性胰管支架置入与高危患者 PEP 发生率较高相关,且不能消除重度 PEP。